ArticleVaccine: X2023

A Phase I study to evaluate safety and tolerability of DTaP-IPV + Hib vaccine in healthy adult volunteers in India.

Hitt Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.